Alzheimer’s disease and immunotherapy

Wei Qin; Yana Pang; Shuya Nie; Meina Quan; Jianping Jia

doi:10.1007/s44194-024-00035-8

Current Medicine ›› 2024, Vol. 3 ›› Issue (1) : 8. DOI: 10.1007/s44194-024-00035-8

Review Article

Alzheimer’s disease and immunotherapy

Wei Qin¹^,²^,³^,⁴^,⁵ ,
Yana Pang¹^,²^,³^,⁴^,⁵ ,
Shuya Nie¹^,²^,³^,⁴^,⁵ ,
Meina Quan¹^,²^,³^,⁴^,⁵ ,
Jianping Jia¹^,²^,³^,⁴^,⁵^,^e

Author information +

History +

Abstract

Alzheimer's disease (AD) is the leading cause of dementia, characterized by neuropathological features such as amyloid-β (Aβ) plaques, neurofibrillary tau tangles, and neurodegeneration. Immunotherapy offers a promising potentially disease-modifying treatment for AD. We review recent advances in AD immunotherapy, specifically focusing on Aβ, tau, and neuroinflammation-targeted approaches, and gain insights from randomized controlled trials to propose disease-modifying directions.

Cite this article

EndNote

Ris (Procite)

Bibtex

Download citation ▾

Wei Qin, Yana Pang, Shuya Nie, Meina Quan, Jianping Jia. Alzheimer’s disease and immunotherapy. Current Medicine, 2024, 3(1): 8 https://doi.org/10.1007/s44194-024-00035-8